Ondansetron oral soluble pellicles vs. azasetron for preventing nausea and vomiting in patients receiving antitumor therapies: a comparative observational study
Related Experiment Video
Updated: May 25, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
Cheng Zhao1, Haibao Cao2, Shuowen Yan2
1Department of Medical Oncology, Anqing Petrochemical Hospital of Nanjing Drum Tower Hospital Group, Anqing, 246002, China.
Objective:
Ondansetron oral soluble pellicles (OSP) show satisfactory effects on preventing nausea and vomiting following antitumor therapies. This study aimed to compare the antiemetic efficacy and safety profiles of ondansetron OSP vs. azasetron in patients receiving antitumor therapies.
Methods:
A total of 110 patients who received antitumor therapies were included in this comparative observational study. According to patient willingness, disease status, and tolerance, 55 patients received ondansetron OSP, and the other 55 patients received intravenous azasetron. During acute and delayed phases, the function living index emesis (FLIE) scale score and degrees of nausea and vomiting [high (46-63 points), moderate (19-45 points), or low (0-18 points)] were assessed. Adverse reactions were collected.
Results:
During the acute phase, FLIE-nausea (5.7 ± 8.9 vs. 17.9 ± 13.6) and vomiting (6.9 ± 7.8 vs. 17.6 ± 13.9) domain scores were lower in patients receiving ondansetron OSP than those receiving azasetron (both P < 0.001). The degrees of nausea and vomiting were lower in patients receiving ondansetron OSP than those receiving azasetron (both P < 0.05). During the delayed phase, FLIE-nausea (5.0 ± 7.9 vs. 10.8 ± 9.1) and vomiting (4.2 ± 6.6 vs. 9.2 ± 8.7) domain scores were lower in patients receiving ondansetron OSP than those receiving azasetron (both P < 0.001). Regarding adverse reactions, the incidence of constipation was lower in patients receiving ondansetron OSP than those receiving azasetron (7.3% vs. 30.9%) (P = 0.003), but the incidence of headache did not differ (P = 0.113).
Conclusion:
Ondansetron OSP possess superior antiemetic effects and safety profiles to azasetron in patients receiving antitumor therapies.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...